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Background: Airway resistance (RAW) and specific airway conductance (sGAW) are measures that reflect the patency
of airways. Little is known of the variability of these measures between different lung diseases. This study
investigated the contribution of RAW and sGAW to a diagnosis of obstructive airways disease and their role in
differentiating asthma from COPD.
Methods: 976 subjects admitted for the first time to a pulmonary practice in Belgium were included. Clinical
diagnoses were based on complete pulmonary function tests and supported by investigations of physicians’
discretion. 651 subjects had a final diagnosis of obstructive diseases, 168 had another respiratory disease and 157
subjects had no respiratory disease (healthy controls).
Results: RAW and sGAW were significantly different (p < 0.0001) between obstructive and other groups. Abnormal
RAW and sGAW were found in 39 % and 18 % of the population, respectively, in which 81 % and 90 % had
diagnosed airway obstruction. Multiple regression revealed sGAW to be a significant and independent predictor of
an obstructive disorder. To differentiate asthma from COPD, RAW was found to be more relevant and statistically
significant. In asthma patients with normal FEV1/FVC ratio, both RAW and sGAW were more specific than sensitive
diagnostic tests in differentiating asthma from healthy subjects.
Conclusions: RAW and sGAW are significant factors that contribute to the diagnosis and differentiation of obstructive
airways diseases.
Keywords: Body-plethysmography, Airway resistance, Pulmonary function tests, Chronic obstructive pulmonary
disease, AsthmaBackground
Whole-body plethysmography is an increasingly frequent
and important component of comprehensive pulmonary
function testing in respiratory medicine, and an integral
diagnostic procedure to evaluate static lung volumes and
airway resistance [1, 2]. To determine airways resistance,
plethysmography applies the gas law of Boyle-Mariotte [3]
to evaluate the difference in the pressure of the closed box
(in which the subject is breathing) in conjunction with
flows measured at the subject’s mouth by breathing out of
the box [4, 5].* Correspondence: Wim.Janssens@uzleuven.be
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creativecommons.org/publicdomain/zero/1.0/The two most commonly used resistive parameters are
airway resistance (RAW) and specific airway conductance
(sGAW). RAW reflects changes in alveolar pressure over
changes in flow [6] representing true resistance of the
airways. RAW is determined by airway narrowing and is
therefore considered a good parameter for the diagnosis
of airflow obstruction [6]. As the manoeuvre to deter-
mine airway resistance is dependent on thoracic gas vol-
ume (with larger volumes resulting in opened airways),
specific airway resistance (sRAW) is divided by thoracic
gas volume to obtain RAW. Mathematically, sRAW does
not represent resistance but the flow-standardized work
that one needs to perform in order to complete the
manoeuvre [4]. SGAW is the inverse of sRAW and there-
fore reflects the conductance of the airways independent
of lung volumes.s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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have lost their interest in measures of resistance which are
generally perceived as useless in the work-up of clinical
problems. A strong case for the use of such measures in
clinical practice recently emerged from a large multicentre
study in Belgium (the Belgian Pulmonary Function Study).
This study demonstrated that regular measurement of air-
way resistance (both RAW and sGAW), one of four most
commonly used pulmonary function tests (PFTs), signifi-
cantly contributes to a reduction in the number of differ-
ential diagnoses and accuracy of final diagnosis [7].
Nevertheless, it is not yet clear how such parameters vary
between different lung disease groups and the extent to
which they may contribute to differentiation between
asthma, COPD and healthy subjects. The aims of the
study were to a) explore the variability of resistance pa-
rameters between established diagnoses of respiratory dis-
eases in a general patient sample, and b) investigate
whether measures of resistance can differentiate between
the obstructive diseases and further refine the diagnosis of
asthma or COPD.
Methods
Study subjects
In total 976 subjects were included from the Belgian Pul-
monary Function Study. This prospective cohort study in-
cludes all successive new subjects from the periods of
June 6th till September 12th 2011, and January 16th till
June 12th 2012 across 33 hospitals in Belgium. Details on
the protocol can be found in the corresponding publica-
tion [7]. All subjects were of Caucasian race aged 18 to
75 years with a history of respiratory complaints (dyspnea,
cough, sputum, wheezing etc.). All performed complete
PFTs at cohort entry including post-bronchodilator
spirometry, measurement of diffusion capacity and
body-plethysmography including measures of lung vol-
umes, airway resistance (RAW) and conductance (sGAW,
only available in 778 subjects). Pulmonologists per-
formed additional tests such as imaging, ECG and other
PFTs to determine diagnosis, where necessary. All final
diagnoses for each included subject were validated by
local Belgian focus groups of 20 to 25 pulmonologists
who jointly evaluated all test outcomes. A final diagno-
sis was selected from a predefined list of 13 diseases
covering the wide spectrum of respiratory diseases that
are potentially diagnosed by pulmonary function: asthma,
COPD, other obstructive diseases, upper airway obstruc-
tion, neuromuscular disease, thoracic or pleural disease,
obesity, interstitial lung disease, systemic sclerosis or vas-
cular disease, cardiac failure, hyperventilation, no primary
pulmonary abnormality, and others (lung cancer, rhinosi-
nusitis, etc.). The study was registered on clinicaltrials.gov
(identifier: NCT01297881).Pulmonary function tests
All PFTs were performed according to the ATS/ERS cri-
teria [8] using standardized equipment available in the
participating pulmonary function laboratory (including:
Sensormedics Whole Body Plethysmograph, Care fusion,
Belgium; Masterscreen Jaeger, Care fusion, Belgium;
Medisoft boybox 5500, Belgium; Ganshoren-Medisoft
Hyp’air compact, Belgium). Spirometry data are post-
bronchodilator measures and expressed, together with
airway resistance and lung volume measurements as per-
cent predicted of normal reference values [9, 10]. SGAW
was calculated by implementing a least-squared fit of the
line through the specific resistance loop at a defined
fixed flow of ±0.5 L/s [5, 11]. Diffusing capacity (DL,CO)
was measured by the single-breath carbon monoxide gas
transfer method and expressed as percent predicted of
reference values [12].
Initial inspection of resistance values (expressed as %
predicted) from healthy subjects (no primary pulmonary
disease) revealed slightly different resistance values than
anticipated. This may be due to limited setting where
existing reference values for resistive parameters were
developed. We therefore established new upper and
lower limits of normality for RAW and sGAW based on a
90 % reference interval from our large healthy reference
population (N = 157). The new proposed upper limit of
normality for RAW was 0.38 (kPa/L/s), corresponding to
173 % of the median healthy population reference value.
The new lower limit of normality for sGAW was 0.63 (1/
kPa*sec) corresponding to 74 % of the reference value.
As with existing reference equations on RAW (median
value 0.22) and sGAW (median value 0.85), no gender
separation was made as no influence on median resistive
values of our healthy reference population was observed.
To explore independency of RAW and sGAW on an in-
dividual patient level, we compared it with other lung
function parameters indicative of the presence of airflow
obstruction. These included: FEV1/FVC ratio, MMEF,
RV, TLC and FRC. If one of the latter was out of the pre-
dicted normal range, it was considered to be disturbed.
Increases in the number of disturbed measures were as-
sociated with increased probability of the presence of
‘true’ airflow obstruction.
Statistical analysis
Statistical Analysis System (SAS) version 9.3, (SAS Institute,
Cary, USA) was used for all statistical analyses. A Shapiro-
Wilk test was used to explore data normality of each
group, and differences between two groups were analysed
via unpaired t-tests or Mann–Whitney tests where normal
or non-normal data distribution existed, respectively.
Logistic-regression models were applied for analysis of
binary variables using stepwise selection to identify the
subset of variables with the strongest relation to the
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default criterion for variables entering or egressing the
models was significance at the 0.15 level. Receiver operat-
ing characteristic (ROC) curve analysis was performed
via GraphPad Prism version 5.01, (GraphPad Software,
La Jolla, California, USA) to identify the best cut-off
values of RAW and sGAW to distinguish between asthma
and COPD diagnoses. New reference values were deter-
mined using MedCalc 14.8.1 (MedCalc Software bvba,
Ostend, Belgium), with Tukey test applied to detect
outliers.
Results
Baseline characteristics
Baseline characteristics of all included subjects are sum-
marised in Table 1 according to three groups, based
upon final diagnosis. The ‘healthy’ group included sub-
jects without primary pulmonary abnormality; the ‘ob-
struction’ group included subjects with COPD, asthma,
upper airway obstruction and other obstructive diseases
(e.g. chronic bronchitis, bronchiolitis, small airways dis-
ease, bronchiectasis, cystic fibrosis); and the ‘other pul-
monary diseases’ group comprised subjects with other,
non-obstructive pulmonary diseases. Consistent with
clinical practice, the ‘obstruction’ group was the most
common diagnostic group (N = 651, 67 % of total sample),
followed by ‘other pulmonary diseases’ (N = 168, 17 %)
and ‘healthy’ (N = 157, 16 %).
Value of resistance parameters for diagnosis of
obstructive airways disease
Median RAW values were greater and median sGAW
values lower in the group of obstructive patients com-
pared to both the healthy controls and the group ofTable 1 Study population characteristics
Healthy
Subjects, n 157
Age, years 53 (41–64)
Smoking, pack yr. 0 (0–5)
BMI, kg/m2 25.3 (21.6–28.7)
FEV1, %predicted 103.3 (91.5–114.7)
FVC, %predicted 106.6 (97.2–114.9)
DLCO, %predicted 86.4 (77.0–99.2)
RV, %predicted 106.9 (91.6–129.7)
TLC, %predicted 104.6 (95.7–112.1)
FRC, %predicted 105.1 (93.4–123.1)
RAW, kPa/L/s 0.24 (0.18–0.30)
sGAW, 1/ kPa*sec 1.21 (0.95–1.57)
Definition of abbreviations: BMI body mass index, DL,CO carbon monoxide diffusing
capacity, FVC forced vital capacity, RV residual volume, RAW airway resistance, sGAW
IQRnon-obstructive respiratory diseases (Table 1). These dif-
ferences were highly statistically significant (both p <
0.0001). Expressed as a percentage of predicted values
using the reference equation of Quanjer [10], the total
study cohort proportion of disturbed RAW (defined as
>150 % predicted of the fixed median value) was 39 %
(N = 377), whilst for sGAW (defined as <50 % predicted) it
was 9 % (N = 73). Eighteen percent of healthy controls had
an abnormal RAW and one had an abnormal sGAW. Imple-
mentation of the lower and upper limits of normal for RAW
and sGAW developed from our own healthy population re-
sulted in a significant change in the proportion of detected
abnormalities. Increased RAW (0.38 kPa/L/s; >173 % pre-
dicted) was observed in only 30 % (N = 290) of subjects,
whilst reduced sGAW (0.63 1/kPa*sec; <74 % predicted) was
observed in 22 % (N = 171) of subjects (Fig. 1). Independ-
ently of the cutoffs used, the group of patients with ob-
structive diseases had a significant higher proportion of
increased RAW. In particular, 47 % of all subjects with ob-
structive airways disease (Panel A) or 37 % if using the less
stringent cut-off (Panel B), presented with an increased re-
sistance. A reduced sGAW (Panels C and D) had a high
positive predictive value for obstructive diseases, as 92 % or
90 % (depending of cut-off) of all cases with low sGAW pre-
sented with such a diagnosis. This was confirmed in the
multiple logistic regression analysis, which identified sGAW
as a significant contributing factor to a diagnosis of ob-
structive lung disease (Table 2). To verify whether resist-
ance parameters (expressed as percent predicted) are
beneficial and additional to other PFT parameters to diag-
nose obstructive airflow disorders, we created different re-
gression models comprising parameters of spirometry only,
parameters from spirometry and body-plethysmography
and by the combination of the former including diffusingObstruction Other pulmonary diseases
651 168
55 (42–65) 57 (44–67)
0 (0–30) 0 (0–15)
25.2 (21.1–29.7) 27.6 (23.1–32.0)
84.2 (67.0–97.7) 88.1 (74.4–103.8)
97.7 (84.4–110.4) 92.1 (76.5–107.8)
78.7 (63.0–89.9) 70.3 (56.3–85.7)
131.6 (104.0–159.9) 101.8 (80.9–124.6)
106.0 (94.8–117.1) 88.6 (79.7–103.4)
119.4 (99.2–143.3) 95.7 (78.0–116.5)
0.32 (0.23–0.45) 0.25 (0.17–0.35)
0.84 (0.56–1.17) 1.28 (0.90–1.71)
capacity, FEV1 forced expiratory volume in one second, FRC functional residual
specific airway conductance, TLC total lung capacity, Values are median and
Fig. 1 Comparison of RAW and sGAW disturbance within each group of diseases and specific obstructive disease. Each panel is divided into three
sections indicating group of diseases and level of disturbance of parameters within each group. Obstructive group is additionally divided into
three subsections representing specific obstructive diseases. Panels a and c/ RAW and sGAW using standard normality limit for disturbance
(>150 %, < 50 % of predicted values); Panels b and d/ RAW and sGAW using statistically drawn limits of healthy subgroup for disturbance;
Disturbance is indicated with the cross hatch in the figure; Data from N = 976 (RAW) and N = 778 (sGAW) subjects, respectively
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however sGAW contributed significantly to all lung function
models.
The presence of abnormal RAW and sGAW values rarely
occurred in isolation and was commonly observed in con-
junction with disturbances of other PFT parameters indi-
cative of obstruction (Table 3). This was particularly
evident for sGAW where only few subjects had normal
values of all other PFT parameters. Of the nine cases of
isolated sGAW disturbance, two were diagnosed as healthy,one had neuromuscular disease, one had another ob-
structive disease, and five had asthma. Additionally, most
subjects who presented with isolated abnormally high
RAW values had a diagnosis of asthma with normal lung
function. Application of the classical cut-offs resulted in
detection of 54 subjects with disturbed resistance, of
which 28 had asthma, 11 were considered healthy, one
had COPD, five presented with other obstructive diseases
and nine had various other respiratory diseases. Our more
restrictive cut-off threshold identified 29 instances of
Table 2 Relationship between pulmonary function parameters
and the presence of obstruction in multiple logistic regression
with stepwise selection
Variables Odds Ratio (95 % Confidence limit) p value
1.
sGAW, %predicted 0.996 (0.994–0.998) 0.0003
MEF75, %predicted 0.980 (0.972–0.988) <0.0001
FEV1/FVC 0.936 (0.912–0.960) <0.0001
2.
TLC, %predicted 1.058 (1.043–1.075) <.0001
sGAW, %predicted 0.997 (0.995–0.999) 0.0031
MMEF, %predicted 0.987 (0.978–0.996) 0.0108
MEF75, %predicted 0.979 (0.969–0.988) <.0001
FEV1, %predicted 0.970 (0.955–0.986) <.0001
1/ Variables of spirometry and resistance (initial model1: FVC, %pred, FEV1,
%pred, FEV1/FVC, MEF75, %pred, MEF50, %pred, MEF25, %pred, MMEF, %pred,
PEF, %pred. RAW, %pred. and sGAW, %pred.); 2/ added variables of lung
volumes (initial model2: model1, TLC, %pred, RV, %pred, FRC, %pred.); Adding
variables of diffusion capacity (initial model3: model2, DLCO, %pred, KCO,
%pred.) resulted in same values as model2
Table 4 Relationship between pulmonary function parameters
and the presence of asthma in multiple logistic regression with
stepwise selection (subjects with obstructive diseases only)
Variables Odds Ratio (95 % Confidence limit) p value
1.
FEV1/FVC 1.043 (1.012–1.074) <0.0001
MEF25, %predicted 1.024 (1.010–1.038) 0.0024
PEF, %predicted 1.018 (1.006–1.030) 0.0088
RAW, %predicted 1.002 (1.000–1.004) 0.0320
2.
FEV1, %predicted 1.029 (1.013–1.046) <.0001
MEF25, %predicted 1.022 (1.010–1.035) 0.0015
RAW, %predicted 1.002 (1.000–1.004) 0.0287
FRC, %predicted 0.981 (0.973–0.989) <.0001
3.
DLCO, %predicted 1.071 (1.051–1.090) <.0001
FEV1/FVC 1.051 (1.024–1.078) <.0001
TLC, %predicted 1.040 (1.014–1.067) 0.0021
FRC, %predicted 0.970 (0.956–0.984) 0.0041
1/ Variables of spirometry and resistance (initial model1: FVC, %pred, FEV1,
%pred, FEV1/FVC, MEF75, %pred, MEF50, %pred, MEF25, %pred, MMEF, %pred,
PEF, %pred. RAW, %pred. and sGAW, %pred.); 2/ added variables of lung
volumes (initial model2: model1, TLC, %pred, RV, %pred, FRC, %pred.); 3/
added variables of diffusion capacity (initial model3: model2,DLCO, %pred,
KCO, %pred.)
Topalovic et al. Respiratory Research  (2015) 16:88 Page 5 of 8disturbed resistance, of which 18 had asthma, six were
considered healthy and five had other respiratory diseases.
Value of resistance parameters for differentiating asthma
from COPD in obstructive airways diseases
Due to the lack of available data for sGAW in some sub-
jects, diagnostic groups differed in size from the principal
analysis, but not in their proportion relative to each other.
Median (IQR) RAW values for the asthma (N = 369) and
COPD (N = 221) groups were 0.30 kPa/L/s (0.22–0.42)
and 0.39 kPa/L/s (0.26–0.53), respectively (p < 0.0001). For
sGAW (N = 286 for asthma; N = 165 for COPD), these were
0.90 1/kPa*sec (0.69–1.22) and 0.60 1/kPa*sec (0.41–0.98),
respectively (p < 0.0001).
When using the complete set of PFTs in the group of
patients with obstructive diseases, application of mul-
tiple logarithmic regression with stepwise selection did
not reveal an independent statistical role for RAW or
sGAW in the differentiation between asthma and COPD.
Although RAW was statistically significant in models in-
volving spirometry and plethysmography parameters
only, the better variable of differentiation was diffusion
capacity (Table 4). When looking at the cumulative dis-
turbances of other PFT parameters per diseased subject,
in COPD, the presence of disturbed RAW or sGAW wasTable 3 Disturbed resistance in relation with the disturbance of oth
RAW (>150 %pred.) RAW (>173 %pred.)
Alone Together Alone Together
54 (=20 %) 218 29 (=14 %) 176
Alone: disturbance of only RAW or sGAW. Some patients excluded from analysis due
and FRCassociated with abnormalities in several other PFT pa-
rameters. For those with asthma, increased RAW more
commonly occurred in isolation (Table 5). The latter
may suggest a more specific role of RAW in the diagnosis
of asthma with a non-obstructive spirometry.
Resistance and specific conductance in non-obstructive
asthma
In COPD, RAW and sGAW were never independently dis-
turbed as significant changes always concurred with sig-
nificant changes of other PFT measures, including the
FEV1/FVC ratio by definition. In contrast, subjects with
asthma, 28 of 112 (28 %) or 18 of 85 (21 %) presented
with isolated RAW disturbance. To further examine this
independent value of resistance in asthma, we focussed
on the subgroup of asthmatics and healthy controls with
normal FEV1/FVC ratio (above LLN) which resulted in a
group of 285 subjects with available RAW data and 213
subjects with available sGAW data. When applying the
maximal sum of sensitivity and specificity to select theer lung function parameters indicative of obstruction
sGAW (<50 %pred.) sGAW (<74 %pred.)
Alone Together Alone Together
1 (=1.5 %) 68 9 (=6 %) 147
to missing measurement data. Included parameters: FEV1/FVC, MMEF, RV, TLC
Table 5 Number of subjects with disturbance per disease (when resistance or specific conductance is already disturbed) stratified
over total number of disturbed lung function parameters indicative of obstruction
Disturbance RAW (>150 %pred.) N = 204
(=31 %)
RAW (>173 %pred.) N = 162
(=25 %)
sGAW (<50 %pred.) N = 61
(=12 %)
sGAW (<74 %pred.) N = 133
(=26 %)
Asthma (N = 112) COPD (N = 92) Asthma (N = 85) COPD (N = 77) Asthma (N = 16) COPD (N = 45) Asthma (N = 55) COPD (N = 78)
0 28 1 18 0 0 0 5 0
1 27 7 23 6 4 0 12 3
2 25 12 19 11 2 2 12 8
3 20 11 16 7 5 4 16 7
4 9 32 6 26 4 19 9 29
5 3 29 3 27 1 20 1 31
Some patients excluded from analysis due to missing measurement data. Proportions observed in a group of all subjects with obstructive diseases. Included
parameters: FEV1/FVC, MMEF, RV, TLC and FRC
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subgroup, ROC curve identified an ideal cut-off value of
0.31 kPa/L/s, with a specificity of 76 %, sensitivity of
45 % and positive predictive value of 78 % (Table 6,
panel A). For sGAW a cut-off value of 0.98 was identified
with associated specificity of 74 %, sensitivity of 50 %
and positive predictive value of 75 % (Table 6, panel B).
Discussion
Our study demonstrates measures of airway resistance
and specific conductance have a valuable and potentially
important role in the diagnosis of obstructive diseases.
Specific conductance clearly contributes to diagnosis of
obstructive airways diseases, whilst airway resistance can
help differentiate between asthma and COPD. The pres-
ence of abnormal resistive parameters in isolation from
other PFT measures may help differentiate between
asthma with normal FEV1/FVC ratio and normal, good
health.
Questions regarding the relevance of resistive param-
eters for diagnosing respiratory diseases are certainly
not new. Prior to this study, it has been shown that
specific resistance (reciprocal of specific conductance)
may indicate bronchial reversibility in asthma, as it has
a different physiological meaning than FEV1 [13]. Most
of its contribution, however, is demonstrated in chil-
dren with asthma where measurement of specific resist-
ance has been shown to improve diagnostic accuracyTable 6 Value of resistance to differentiate between healthy
subjects and asthma patients with normal FEV1/FVC ratio
Asthma (N) Control (N) Total (N)
A RAW > 0.31 129 37 166
RAW ≤ 0.31 156 120 276
Total (N) 285 157 442
B sGAW < 0.98 106 35 141
sGAW≥ 0.98 107 101 208
Total (N) 213 136 349and decrease diagnostic delay [14–16]. Interestingly, it
has also been shown that specific resistance has a better
role in predicting asthma then airway resistance [17],
and has higher sensitivity than FEV1 in terms of detect-
ing lung function changes during methacholine chal-
lenges [18]. In COPD, both specific conductance and
airway resistance are more sensitive for assessing short-
acting bronchodilator effects than FEV1 [18, 19]. Increased
airway resistance and decreased specific conductance have
also been detected as early features of mild COPD
[20, 21]. Detailed analysis of computer tomography scans
shows that increased airway resistance in COPD is corre-
lated with the thickening of the airway walls [22]. Our data
are in line with these earlier observations, but provide a
more comprehensive overview of the role of resistance
and specific conductance in a large unbiased sample of
a routine respiratory practice in conjunction with other
pulmonary function tests. Although resistance and spe-
cific conductance overlap with the disturbed pattern of
pulmonary function tests in patients with a respiratory
disorder, in some subtypes, they may reveal unique
components to suggest a certain diagnosis. We demon-
strate that both parameters have their specific characteris-
tics which are not the leading but yet still significant
contributors to respiratory disease diagnosis.
As expected, the highest frequency of abnormal resist-
ance and specific conductance was found in patients
with obstructive airways diseases, particularly COPD.
RAW abnormalities were present in 50 % of subjects with
mild COPD stages (former GOLD I and II, 75 % of all
COPD cases), This proportion rose to 91 % in those with
more severe disease (former GOLD III and IV). Whilst
fewer subjects had disturbed sGAW, specific conductance
appeared more useful than resistance in distinguishing
obstructive diseases from non-obstructive, healthy or re-
strictive diseases. To some extent this may be explained by
the fact that sGAW is independent of the thoracic gas vol-
ume [23] and may thus differentiate disturbed resistances
of smaller airways at low lung volumes (e.g. interstitial lung
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cases of asthma and COPD [24]. The observation that RAW
pops up again when it comes to the further differentiation
of asthma from COPD, may be explained by the fact that
disproportionally low resistances (by high thoracic gas vol-
umes) for the level of airflow limitation and FEV1 reduc-
tion, is a specific characteristic of COPD [25]. Moreover,
our data demonstrate that an isolated increase of RAW
might be associated with a diagnosis of asthma when
airflow limitation on spirometry is not present. Mech-
anistically, disturbed FEV1 measures may be seen as a
consequence of increased airway resistance from cen-
tral and peripheral airways. However, FEV1 is obtained
from the first second of forced expiration and therefore
poorly representative of the small airways. The latter
are better visualized at the end of a forced expiration or
eventually, by direct measures of resistance during tidal
breathing [26, 27].
The most appropriate predictive cut-off values to
identify normality of resistive and conductive parame-
ters are contentious. A thorough evaluation of our
healthy subject population using the current recom-
mended reference equations yielded unsatisfactory re-
sults and indicated that the current reference values
may not be up to date [10, 28]. Evaluation of these data
using the predicted median and 90 % confident inter-
vals in our healthy reference population (which was
considered healthy after an extensive evaluation includ-
ing all necessary tests) showed the cut-offs for RAW to
be too liberal and the cut-offs for sGAW too restrictive.
Despite calls for revision of these reference equations
from different authors, no official action has been taken
yet [28, 29]. Solving this problem may lead to a more
accurate and better usability of this test in clinical set-
tings as current predictive values were not constituted
in a large and healthy representative population.
An inherent limitation of our multi-centre study may
lie in its design to measure pulmonary function using
variety of equipment, since it can affect variability and
consistency of obtained measurements. Weaknesses of
airway resistance and specific conductance are also ap-
parent within the analysis. For example, it is clear that
both resistive parameters have large variability within
core groups, making them weak independent factors for
disease differentiation [30]. Another weakness lies in the
estimation process for specific conductance, which af-
fects estimation of airway resistance as well. Practically,
the line fitted through the resistance loop to calculate
sGAW does not always accurately reflect the entire loop
pattern. Often, these differences can be visually detected
(e.g. widening of the loop, club-shaped format, S pattern,
etc. [4]) but may result in similar inclinations. Add-
itional exploration specifically focused on the pattern of
such resistive loops will increase the value of theseparameters and may result in a better description of
certain phenotypes.
Taken together, airway resistance and specific conduct-
ance are certainly not the grand slam winning parame-
ters of pulmonary function tests, however they can
significantly contribute to the diagnosis of obstructive
diseases and further disease differentiation. Our data
also indicate that changing the upper limit of normality
for RAW to 0.38 kPa/L/s and accepting a new lower limit
of normality for sGAW (0.63 1/kPa*sec) may even im-
prove their diagnostic value.
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